Overview of OEA and its Effects
Oleoylethanolamide (OEA) is a lipid that promotes hypophagia (reduced appetite) and aids in decreasing fat mass. It is synthesized from oleic acid and omega-9 during digestion. However, factors like gut dysbiosis, obesity, and the consumption of ultra-processed foods may impair OEA production.
Clinical Study Highlights
A clinical study in Brisbane, Australia, assessed the effects of OEA on serum levels of glucagon-like peptide-1 (GLP-1), a hormone important for glucose regulation. Key points include:
- Participants: 43 overweight and obese individuals, free of metabolic disorders, participated in a randomized, placebo-controlled, crossover trial.
- Dosage: Participants consumed OEA at a dosage of 300 mg (two capsules of TRPTI, each containing 150 mg) or placebo after an overnight fast.
- Primary Outcome: GLP-1 levels increased significantly—by 20% to 25%—within 15 minutes post-supplementation with OEA.
Study Methodology
Participants had standardized meals at set intervals and their blood samples were monitored for hormone levels over an eight-hour period. Hormones measured included:
- GLP-1
- Glucose-dependent insulinotropic polypeptide (GIP)
- Dipeptidyl peptidase-4 (DPP-4)
Immediate Effects of OEA
The 300 mg dosage of OEA resulted in:
- Initial GLP-1 Increase: Levels started rising after just 15 minutes.
- Sustained Effects: Even four hours post-dose, the GLP-1 levels remained significantly elevated in the OEA group compared to placebo.
- Mechanism: The consistency suggests a nutrient-dependent process rather than a transient response.
Microbiome Connections
The research indicated that:
- OEA might influence gut microbiome health, leading to weight loss and reduced intestinal inflammation.
- An increase of 21% in baseline GLP-1 levels was noted from the beginning to the end of microbiome studies.
Potential Applications
Ramasamy Venkatesh, managing director of Saanroo, posited that OEA could serve as a more efficient alternative to GLP-1 receptor agonists, which are known to have side effects. The findings support OEA’s role in enhancing the body’s own mechanisms for GLP-1 production, which could lead to new health claims for OEA-based products in markets such as the US, Australia, and Canada.
Future Research Directions
Upcoming studies aim to explore OEA’s impact on metabolic health and its effectiveness at lower doses (like 50 mg). Further pharmacokinetic studies will compare OEA’s bioavailability against standard formulations.
For more detailed information, refer to the published study: Frontiers in Endocrinology.
